Coherus Stock Plummets as FDA Rejects Neulasta Biosimilar

Short resume:

coherus
80%
data
60%
amgen
50%
stock
40%

Coherus Biosciences, Inc.CHRS shares declined nearly 24% in yesterday’s trading as it announced that it has received a complete response letter (CRL) from the FDA for its biosimilar version of Amgen Inc’s AMGN blockbuster drug, Neulasta.
Source Nasdaq
Read More…

More News


Be the first to comment

Leave a Reply

Your email address will not be published.


*